Last updated on June 2017

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Brief description of study

To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.

Clinical Study Identifier: NCT02947165

Contact Investigators or Research Sites near you

Start Over

Todd M. Bauer

Tennessee Oncology SC
Nashville, TN United States
  Connect »